PreveCeutical Medical (PREV) Price & Analysis

Compare

12 Followers

PREV Stock Chart & Stats

C$0.02

C$0.00(0.00%)

At close: Jan 08 4:00 PM EST

C$0.02

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$0.02 - C$0.06

Previous CloseN/A

Volume100.00K

Average Volume (3M)143.42K

Market Cap

C$11.74M

Enterprise ValueC$16.23M

Total Cash (Recent Filing)C$103.68K

Total Debt (Recent Filing)C$4.60M

Price to Earnings (P/E)―

Beta-0.26

Next Earnings

May 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding586,811,950

10 Day Avg. Volume276,937

30 Day Avg. Volume143,419

Financial Highlights & Ratios

PEG Ratio114.24

Price to Book (P/B)-2.02

Price to Sales (P/S)0.00

P/FCF Ratio-31.30

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused R&D In Pharmaceutical And Cannabinoid TherapeuticsThe company’s explicit focus on pharmaceutical and therapeutic technologies, including cannabinoid delivery platforms and drug-development programs, provides a clear strategic niche. A sustained R&D focus in a specialized therapeutic area can yield durable IP, regulatory pathways, and differentiated products if programs advance.

Corporate Restructuring And Financing ActionsCompletion of a spin-off and a private placement represents a structural corporate realignment and an infusion of capital. These actions can sharpen management focus on core programs and temporarily shore up liquidity, improving the company’s runway and execution capacity over the medium term.

Improving Free Cash Flow TrendWhile free cash flow remains negative in absolute terms, the positive growth metric vs. the prior period signals some improvement in cash conversion and expense control. If management sustains this trend, it supports longer-term cash stability and reduces immediate financing pressure.

Bears Say

No Revenue And Widening Operating LossesAbsence of operating revenue alongside widening losses is a fundamental weakness: it indicates lack of commercial validation and forces reliance on financing. Persisting negative earnings means continued cash drain and raises execution risk over the next several months absent product or partnership commercialization.

Stressed Balance Sheet: Negative Equity And High LeverageDeeply negative equity and debt that materially exceeds a thin asset base sharply reduce financial flexibility. This capital structure elevates default and dilution risk, constrains strategic options, and makes the company vulnerable to funding shortfalls over a multi-month horizon.

Ongoing Cash Burn And Reliance On External FundingSustained negative operating and free cash flow require frequent external financing. Reliance on placements and restructurings is a structural risk: future program advancement and shareholder dilution hinge on the company’s ability to raise capital, threatening continuity if markets tighten.

PreveCeutical Medical News

PreveCeutical Files Patent for Direct Brain Delivery of Dopamine and CNS Drugs

PreveCeutical Medical ( ($TSE:PREV) ) has shared an announcement. PreveCeutical Medical has filed an international patent application for...

7d ago

PreveCeutical and BioGene Complete Strategic Spin-Off Arrangement

PreveCeutical Medical ( ($TSE:PREV) ) has shared an update. PreveCeutical Medical Inc. and BioGene Therapeutics Inc. have completed...

3M ago

PreveCeutical Finalizes Arrangement with BioGene to Expand Market Reach

The latest update is out from PreveCeutical Medical ( ($TSE:PREV) ). PreveCeutical Medical Inc. announced the completion of...

3M ago

PreveCeutical Clarifies Shareholder Arrangement with BioGene

An announcement from PreveCeutical Medical ( ($TSE:PREV) ) is now available. PreveCeutical Medical Inc. announced a clarification regarding...

3M ago

PreveCeutical Completes Second Tranche of Private Placement

PreveCeutical Medical ( ($TSE:PREV) ) has provided an update. PreveCeutical Medical Inc. has successfully closed the second tranche...

4M ago

PreveCeutical Completes Strategic Arrangement with BioGene

PreveCeutical Medical ( ($TSE:PREV) ) has shared an announcement. PreveCeutical Medical Inc. has announced the completion of its...

4M ago

PreveCeutical Expands Financing and Approves Key Resolutions at Annual Meeting

PreveCeutical Medical ( ($TSE:PREV) ) has provided an update. PreveCeutical Medical Inc. announced the approval of all resolutions...

4M ago

PreveCeutical Prepares for Shareholder Meeting on BioGene Arrangement

PreveCeutical Medical ( ($TSE:PREV) ) has shared an announcement. PreveCeutical Medical Inc. has announced the mailing and filing...

5M ago

PreveCeutical Completes Initial Tranche of Private Placement

An announcement from PreveCeutical Medical ( ($TSE:PREV) ) is now available. PreveCeutical Medical Inc. has successfully closed the...

5M ago

PreveCeutical Announces Spin-Out of BioGene Shares to Shareholders

PreveCeutical Medical ( ($TSE:PREV) ) has issued an update. PreveCeutical Medical Inc. has announced a definitive arrangement agreement...

5M ago

PREV FAQ

What was PreveCeutical Medical Inc’s price range in the past 12 months?

PreveCeutical Medical Inc lowest stock price was C$0.01 and its highest was C$0.06 in the past 12 months.

What is PreveCeutical Medical Inc’s market cap?

PreveCeutical Medical Inc’s market cap is C$11.74M.

When is PreveCeutical Medical Inc’s upcoming earnings report date?

PreveCeutical Medical Inc’s upcoming earnings report date is May 06, 2026 which is in 79 days.

How were PreveCeutical Medical Inc’s earnings last quarter?

PreveCeutical Medical Inc released its earnings results on Dec 01, 2025. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.

Is PreveCeutical Medical Inc overvalued?

According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PreveCeutical Medical Inc pay dividends?

PreveCeutical Medical Inc does not currently pay dividends.

What is PreveCeutical Medical Inc’s EPS estimate?

PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PreveCeutical Medical Inc have?

PreveCeutical Medical Inc has 586,811,950 shares outstanding.

What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?

PreveCeutical Medical Inc reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of PreveCeutical Medical Inc?

Currently, no hedge funds are holding shares in TSE:PREV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PreveCeutical Medical Inc

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.